Melatonin and prostate cancer cell proliferation: Interplay with castration, epidermal growth factor, and androgen sensitivity
The Prostate2002Vol. 52(2), pp. 106–122
Citations Over Time
Abstract
Together with previous data, the present results indicate synergistic action of melatonin and castration in inhibiting the growth of androgen-sensitive LNCaP tumor. Androgen-sensitive prostate cancer cell proliferation may be modulated by opposite changes in cyclin D1 levels induced by activated MT(1) and EGF receptors. In androgen-insensitive prostate cancer cells, MT(1) receptor-mediated signal transduction may become defective not only through changes in membrane receptor protein expression and/or functions, but also by means of alterations in downstream postreceptor signaling events.
Related Papers
- → Loss of response to melatonin treatment is associated with slow melatonin metabolism(2010)92 cited
- → Serum melatonin levels in melanoma patients after repeated oral administration(1994)11 cited
- → Biological significance of measurable androgen levels in the rat ventral prostate following castration(1987)64 cited
- → The Effects of Melatonin Treatment on Oxidative Stress Induced by Ovariohysterectomy in Dogs(2020)3 cited
- → (1981)